Aktienanalyse zu Danaher Corp (DHR)DHRDanaher Corp

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services. The Company also provides pulse oximetry and other patient monitoring solutions, primarily in acute care treatment settings. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).

Danaher Corp is a good buy right now due to its current price of $219.81, which is below the average analyst price target of $250, indicating a potential upside of approximately 13.7%. Additionally, the stock has shown a positive trend with a 20-day change of +9.83% and a healthy RSI of 54.58, suggesting it is neither overbought nor oversold. The main risk is its high P/E ratio of 38.18, which may indicate overvaluation if growth does not meet expectations.

17 analysts cover DHR: 13 rate it Buy, 4 Hold and 0 Sell. The average price target is 266.18.